It is expected that a price bounce should occur soon.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 191 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 191 cases where SMTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 56 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 61 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (38.332) is very high in comparison to the industry average of (4.887). P/E Ratio (-8.909) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TWST declined for three days, in 272 of 316 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 39 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 64 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 37 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
TWST moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 233 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 185 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.790) is normal, around the industry mean (2.978). P/E Ratio (-62.677) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SMTI | TWST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 96 | 87 | |
SMR RATING 1..100 | 99 | 97 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 97 | 93 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TWST's Valuation (4) in the Biotechnology industry is significantly better than the same rating for SMTI (81) in the null industry. This means that TWST’s stock grew significantly faster than SMTI’s over the last 12 months.
TWST's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as SMTI (96) in the null industry. This means that TWST’s stock grew similarly to SMTI’s over the last 12 months.
TWST's SMR Rating (97) in the Biotechnology industry is in the same range as SMTI (99) in the null industry. This means that TWST’s stock grew similarly to SMTI’s over the last 12 months.
TWST's Price Growth Rating (50) in the Biotechnology industry is in the same range as SMTI (50) in the null industry. This means that TWST’s stock grew similarly to SMTI’s over the last 12 months.
TWST's P/E Growth Rating (93) in the Biotechnology industry is in the same range as SMTI (97) in the null industry. This means that TWST’s stock grew similarly to SMTI’s over the last 12 months.
| SMTI | TWST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 83% |
| MACD ODDS (%) | N/A | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| Advances ODDS (%) | 9 days ago 75% | 16 days ago 80% |
| Declines ODDS (%) | 2 days ago 77% | 5 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 81% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SMTI’s FA Score shows that 0 FA rating(s) are green while TWST’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SMTI’s TA Score shows that 4 TA indicator(s) are bullish while TWST’s TA Score has 3 bullish TA indicator(s).
SMTI (@Pharmaceuticals: Other) experienced а -5.72% price change this week, while TWST (@Biotechnology) price change was -7.96% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.91%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was +7.66%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.95%. For the same industry, the average monthly price growth was -13.78%, and the average quarterly price growth was -13.62%.
SMTI is expected to report earnings on Nov 16, 2026.
TWST is expected to report earnings on Nov 13, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (+2.95% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIA | 518.92 | -0.18 | -0.03% |
| State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) | |||
| GVLU | 28.25 | -0.02 | -0.08% |
| Gotham 1000 Value ETF (GVLU) | |||
| BSJR | 22.10 | -0.08 | -0.34% |
| Invesco BulletShares 2027 High Yield Corporate Bond ETF (BSJR) | |||
| QIG | 42.39 | -0.20 | -0.48% |
| WisdomTree U.S. Corporate Bond Fund (QIG) | |||
| IBGA | 22.69 | -0.13 | -0.56% |
| iShares iBonds Dec 2044 Term Treasury ETF (IBGA) | |||